Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2017.02.30
Abstract: Targeting CD47 is in the spotlight of cancer immunotherapy. Blocking CD47 triggers the recognition and elimination of cancer cells by the innate immunity. There are three CD47 antagonists in phase I clinical trials, but their… read more here.
Keywords: cd47; targeting cd47; cd47 achievements; cancer immunotherapy ... See more keywords